Which drug class does enzalutamide belong to? What diseases are mainly treated?

Enzalutamide, also known as enzalutamide, is an oral nonsteroidal androgen receptor inhibitor. It effectively blocks the signaling of androgen receptor (AR) through a multi-target mechanism, including inhibiting the binding of AR to hormones and blocking AR enters the cell nucleus and inhibits the combination of AR and DNA, thereby inhibiting the growth and spread of tumor cells. Enzalutamide belongs to a new generation of antiandrogens and plays an important role in the treatment of prostate cancer.

Enzalutamide is mainly used to treat prostate cancer, especially castration-resistant prostate cancer (CRPC). Although these patients have reduced androgen levels in their bodies through drugs or surgery, tumor cells can still continue to grow relying on androgen receptor signals. Enzalutamide blocks this pathway, thereby delaying disease progression and improving patient survival.

In addition, enzalutamide is also used in the treatment of non-metastatic castration-resistant prostate cancer, aiming to delay the occurrence of bone metastases. Clinical studies have shown that enzalutamide can significantly prolong metastasis-free survival and improve patients' quality of life, making it one of the standard treatment options for prostate cancer at this stage.

In conclusion, enzalutamide, as a highly potent androgen receptor inhibitor, plays a key role in multiple stages of prostate cancer, especially castration-resistant prostate cancer. Its oral administration method and good tolerability make it an important drug in clinical treatment, helping patients prolong their lives and improve their quality of life.

Reference materials:https://www.drugs.com